Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials

<p><strong>Background</strong></p> Despite highly effective targeted therapies for rheumatoid arthritis, about 40% of patients respond poorly, and predictive biomarkers for treatment choices are lacking. We did a biopsy-driven trial to compare the response to rituximab, etane...

Full description

Bibliographic Details
Main Authors:	Rivellese, F, Nerviani, A, Giorli, G, Warren, L, Jaworska, E, Bombardieri, M, Lewis, MJ, Humby, F, Pratt, AG, Filer, A, Gendi, N, Cauli, A, Choy, E, McInnes, I, Durez, P, Edwards, CJ, Buch, MH, Gremese, E, Taylor, PC, Ng, N, Cañete, JD, Raizada, S, McKay, ND, Jadon, D, Sainaghi, PP, Stratton, R, Ehrenstein, M, Ho, P, Pereira, JP, Dasgupta, B, Gorman, C, Galloway, J, Chinoy, H, van der Heijde, D, Sasieni, P, Barton, A, Pitzalis, C
Other Authors:	STRAP collaborative group
Format:	Journal article
Language:	English
Published:	Elsevier 2023

Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials

Similar Items